Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger. The resulting company will continue under the Alumis name at the ...

Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 program in first ...

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement for an all-stock transaction, with stockholders of each company owning approximately 55% and 45% of the combined entity ...

Alumis (ALMS) and Acelyrin (SLRN) announced a definitive merger agreement under which Alumis and Acelyrin will merge in an all-stock transaction. Alumis and Acelyrin had cash, cash equivalents and ...

The South San Francisco company (Nasdaq: ALMS) also will gain a drug, called lonigutamab, for thyroid eye disease from merger partner Acelyrin Inc. (Nasdaq: SLRN), but it said Thursday it will ...

Biopharmaceutical companies Alumis and ACELYRIN said Thursday they have agreed to a merger which will see the combined company operate under the Alumis name with the current Alumis executive team.

Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former lead candidate that began with the axing of development in two diseases in August.

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which ...